{"section": [{"title": "Remarks by Patrick Donnelly", "id": 1, "section": [{"id": 2, "text": "Hey, guys. Thank you for taking the question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Patrick Donnelly\", \"section_number\": 1, \"uuid\": \"f88bd02b-47ee-4d54-91d3-cfca1b605337\", \"speaker_title\": \"Analyst at Citi Group\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 3, "section": [{"id": 4, "text": "Hey Patrick.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 2, \"uuid\": \"c8a5ea26-8e6b-4bf3-bf9c-cc0bc96cbd6b\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Patrick Donnelly", "id": 5, "section": [{"id": 6, "text": "Hey, how are you? Maybe one for you on the Breast Health side. It sounds like the gantry backlog continues to build good order pace can you just talk, I guess, about the visibility into that chip improvement? Obviously, again the guidance kind of implies as the year goes, you guys talked about the exit rate. I think it improved kind of mid-year. But yeah, I mean just talking about the visibility there again on the order side, are you seeing any share shift or kind of customers staying with you guys through this and then similarly, just on kind of staying on the gantry you mentioned even in a recession feel pretty good about what the -- what the order growth would look like. What gives you that confidence? A lot of questions about hospital capex obviously this maybe just focus on the gantries [Indecipherable] I would appreciate it.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Patrick Donnelly\", \"section_number\": 3, \"uuid\": \"86f4d7b4-67c8-4e62-b7cf-ff85d8e01563\", \"speaker_title\": \"Analyst at Citi Group\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 7, "section": [{"id": 8, "text": "Sure, Pat. I think what we feel great about is over time, and we haven't built the market share in the installed base in the United States and really around the world, especially in the U.S. without people really buying into the superiority of our products from a labeling, from a workflow standpoint, from a clinical efficacy published data everything else that we're doing to both detect earlier stage cancers sooner also reducing the false positives and avoiding needless callbacks, people have really seen that. So when it comes down to a hospital system is looking to meet a few new gantries for their system. They're not going to want to go away from us because they've made that decision to come into us. So they're much more willing to wait until we're back in business plus the other reality is this is an across-the-board industry issue.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 4, \"uuid\": \"1f051c93-5c01-4eb0-9812-5d02fc0967fc\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}, {"id": 9, "text": "So it's not like we are short and others can provide. So we really have two things going for us, which is call it the micro our products and the incredible products we're offering and the macro that what we're dealing with the chip issues being felt by everybody else. So I think our customers understand that I think anybody who's in purchasing or work for hospital they all understand the supply chains and their own personal lives. Right. You need a dishwasher fixed and the parts taking months to get those kinds of things that are playing out in everybody's like. I think everybody understands okay, is going to be a little while. So we feel great about customers continuing to want our products and feeling better and better about our visibility into as we've been working with all the chip vendors right down to every single SKU and how many ships go into every one of our machines feeling better and better about where we'll go.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Stephen MacMillan\", \"section_number\": 4, \"uuid\": \"1f051c93-5c01-4eb0-9812-5d02fc0967fc\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Patrick Donnelly", "id": 10, "section": [{"id": 11, "text": "Okay, that's helpful and then maybe on the back of that you mentioned in terms the op [Phonetic] margins COVID is going to be heavier in the first half, which is margin accretive but at the same time as we just talked through their receive the Breast Health recoveries be more second half that's been a drag on margins. How should we think about the op margin cadence throughout the year. I know you talked about 30% for the year, but maybe just talk about how that rolls through given the moving pieces to COVID Breast Health. Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Patrick Donnelly\", \"section_number\": 5, \"uuid\": \"5150fb06-4330-46b6-841b-ffe4179f5acc\", \"speaker_title\": \"Analyst at Citi Group\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 12, "section": [{"id": 13, "text": "Yeah, I mean I would think the 30% is probably pretty consistent throughout the quarters of the year. As you said the dynamics kind of change first half versus back half. So I think that 30% plus or minus in any quarter pointed to, I think, I think you're right on.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 6, \"uuid\": \"194fb066-fe08-44b3-9fd0-2edf39615057\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Tejas Savant", "id": 14, "section": [{"id": 15, "text": "Hey guys, good afternoon. Karleen just following up on that margin question here a little bit, can you just call out specifically in terms of the COVID contribution assumptions you're baking in here, remind us of what the gross and operating margin assumptions are for that piece versus the rest of the business?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Tejas Savant\", \"section_number\": 8, \"uuid\": \"c9e897ee-d0f3-46b2-8fed-c05b9f9171fb\", \"speaker_title\": \"Analyst at Morgan Stanley\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 16, "section": [{"id": 17, "text": "Yeah, Tejas why don't we just say that -- what we've noted in the prepared remarks is that COVID is accretive to the corporate averages, but we haven't disclosed that specifically. And I'd also add on that when you think about in this macro environment in our initial guidance for the full year to say that our margins, operating margins going to be at 30%, which are pretty rich compared to the industry is pretty strong results and we're really proud of that and actually even if you look at our net margin, prior to pre-pandemic levels, which were around 20% our guide would imply that the roughly 22% to 23% really reinforcing our earnings power.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 9, \"uuid\": \"69559ca0-ca1d-4d1d-b2d7-41a3d4d17da9\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Tejas Savant", "id": 18, "section": [{"id": 19, "text": "Got it. That's helpful and then just a quick follow-up there in terms of the ranges you've baked into the guide Karleen, can you just walk us through what's assumed for the Breast Health recovery at the high end of the guide, are you assuming essentially a return to normalcy by the fourth quarter or is there still some possibility of the recovery taking a little bit longer.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Tejas Savant\", \"section_number\": 10, \"uuid\": \"c5232d8b-f757-44c8-8a9d-972070bcc631\", \"speaker_title\": \"Analyst at Morgan Stanley\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 20, "section": [{"id": 21, "text": "Yeah, I think the guidance would imply that we're approaching normalized levels as we exit the year. I would also say that part of the recovery, even if we did get incremental gantry chips than anticipated this resource limitations as our field service engineers who maintains the installed base also do the actual installs in any quarter. So there will be a balance through this recovery, but in general, think about a gradual sequential recovery throughout the course of the year and exiting close to normal levels.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 11, \"uuid\": \"1ec33a3a-fb2e-4e5f-bd28-899923587d18\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Tejas Savant", "id": 22, "section": [{"id": 23, "text": "Got it. Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Tejas Savant\", \"section_number\": 12, \"uuid\": \"dc86c1e1-a4c6-4338-8186-f88912ded276\", \"speaker_title\": \"Analyst at Morgan Stanley\"}"}]}, {"title": "Remarks by Anthony Petrone", "id": 24, "section": [{"id": 25, "text": "Thanks and congratulations on a strong finish to the year-end and good to see at least some visibility into calendar '23, just given the headwinds. I guess I'm going to start on COVID testing and just the guidance that was issued here and then a follow-up on broader diagnostics, understanding that it's still tough to forecast pandemic ebbs and flows. But maybe perhaps one of the things that is sort of becoming evident here is the tender patterns, whether it be from large lab entities or even governmental contracts. And so when you think into 2023, is there any incremental visibility that you can point to as it relates to just larger tenders, whether it'd be U.S. OUS [Phonetic] at the hospital level or at the government level and then I'll have a follow-up on broader diagnostics. Thanks.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Anthony Petrone\", \"section_number\": 14, \"uuid\": \"7c89c0df-eb11-48df-99bd-a66f64b328d1\", \"speaker_title\": \"Analyst at Mizuho\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 26, "section": [{"id": 27, "text": "Yeah, I wouldn't say we've got any more visibility. We've been very close to our customers all along, Anthony. In terms of both international from the Ministry of Health deciding things right down to the regional authorities within various countries and the same within every one of our customers in the U.S., both the main labs as well as the hospitals. So I think we continue to stay close and feel very good about our position and the way we continue to think about COVID is we're going to deliver whatever the marketplace needs. We're not going to get over our skis in terms of forecasting it financially.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 15, \"uuid\": \"a98c4121-5b4a-4ffc-8375-a5e880b62f39\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Anthony Petrone", "id": 28, "section": [{"id": 29, "text": "And then in terms of just quick follow-up on COVID. I mean, as we think of it as a consistent cash flow driver we even look ahead maybe beyond 2023 what point do testing providers really look at this as a relatively consistent cash flow business that reliably again there's going to be a contributor going forward. So just kind of the broader views on the consistency of COVID. And then lastly, diagnostics, when you think it's testing intensity a lot of new Panther users are. How do you think that plays out [Technical Issues], just beyond the point we are here at the end of this fiscal year. Thanks again.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Anthony Petrone\", \"section_number\": 16, \"uuid\": \"321e0000-3bae-4fa0-987b-23d00119c79e\", \"speaker_title\": \"Analyst at Mizuho\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 30, "section": [{"id": 31, "text": "Thanks. We didn't fully hear the second part of that question, because you were cutting in and out on the first part, as it relates to the first part of the follow-up in terms of consistency on COVID, I think the way we've approached this all along has been, you can't predict this has never been consistent. It has been volatile by region and by timeframe and at any 8-week period, people have been way off probably trying to predict what was about to happen. So again, what we have said at the beginning, however, was we thought that this long-term would create a new Assay for us that would be far more enduring than I think anybody ever thought it would be back in 2020 back to what people thought when everybody thought this was going to go away in a hurry, or it was going to go away as soon as vaccines arrive, or molecular testing was going to go away as soon as antigen tests came along.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 17, \"uuid\": \"041f8fc8-70e7-4010-b924-e40e2a146d82\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}, {"id": 32, "text": "Right, what we've learned is this thing is going to be around. And frankly, as long as countries like China, are still trying zero COVID approach and everything else and the fact that this thing, we always said in the beginning, this is a respiratory virus that will mutate. Herd immunity was never going to be achieved. And we thought we would end up with an enduring business. Whether that enduring business ends up being $150 million or $200 million, we really don't know, but we feel really good that we're in that business. Thank you.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Stephen MacMillan\", \"section_number\": 17, \"uuid\": \"041f8fc8-70e7-4010-b924-e40e2a146d82\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Anthony Petrone", "id": 33, "section": [{"id": 34, "text": "Thank you. I'll hop back in.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Anthony Petrone\", \"section_number\": 18, \"uuid\": \"f7c187ec-7177-47b7-8346-4d1fdee85b1b\", \"speaker_title\": \"Analyst at Mizuho\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 35, "section": [{"id": 36, "text": "Right.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 19, \"uuid\": \"a3d17f93-f8de-42b6-b2d8-7988c6180a57\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Jack Meehan", "id": 37, "section": [{"id": 38, "text": "Thank you. Good afternoon.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jack Meehan\", \"section_number\": 21, \"uuid\": \"8b64d22c-ef93-4bff-88ec-926b8147ca23\", \"speaker_title\": \"Analyst at Nephron Research\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 39, "section": [{"id": 40, "text": "Jack [Indecipherable]. All right. [Indecipherable].", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 22, \"uuid\": \"087696a7-549b-4759-a1bb-f0f8ac7eaf73\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Jack Meehan", "id": 41, "section": [{"id": 42, "text": "I have a couple of questions on molecular testing. Before I go, trick or treating. The first is on the COVID sales. So I think, based on your disclosures, it sounds like the U.S. Assay sales were about $105 million, which was pretty stable sequentially and I look at the government PCR data volumes were down 27% quarter-over-quarter. So I just curious on the COVID side, if you could talk about either share dynamic or was there any end-of-quarter ordering into the respiratory season? Any color on that would be great.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jack Meehan\", \"section_number\": 23, \"uuid\": \"a47ecdc5-9857-4763-8b67-51c8a324daed\", \"speaker_title\": \"Analyst at Nephron Research\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 43, "section": [{"id": 44, "text": "It's hard for us to fully know. On the share stuff because of the various pieces. I would say, there were no unusual ordering patterns at quarter end. So none of this was stocking up for fourth quarter. We generally -- our business is very diversified. And I think one of the things we did, as you well know early in the pandemic is we went out to a very broad customer base. And I think that has helped insulate and provide a little more enduring nature to our business. It's also helped our pricing hold up reasonably well. So I think we feel pretty good, but we just continues to go and regions and spikes and this it does feel like U.S. testing is kind of settling in for the first time to a more normalized pattern and we're still -- we're starting to see that certainly in our own business, but no unusual spikes.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 24, \"uuid\": \"5b7f50cf-965d-4328-a08c-f5fb466f8b58\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Jack Meehan", "id": 45, "section": [{"id": 46, "text": "Of course [Phonetic] and then is my second question. So I appreciate the commentary about the new customers 85% earning more than one, 55% more than two. Is there any color you can share on like what are they running is this beyond respiratory testing and I don't know if you have the stats handy, but how large is the Virology business, if I look at the full year, how large is the vaginitis business, any updates on those would be great.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jack Meehan\", \"section_number\": 25, \"uuid\": \"a2063fd1-ddf5-4658-91d1-cd75f6ebd4c9\", \"speaker_title\": \"Analyst at Nephron Research\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 47, "section": [{"id": 48, "text": "Yes, I think we stopped disclosing the actual number on that, but very strong growth year-over-year in that business continues to have a nice trajectory. I would say that it's diverse on the other assays, but probably leaning towards the core women's health assays primarily. Thank you, Karleen.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 26, \"uuid\": \"6be80dfb-077f-417c-9593-ffac70afeeef\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 49, "section": [{"id": 50, "text": "Let's do a trick or treat.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 27, \"uuid\": \"0a299663-0443-4628-bc29-6e03b952bfb6\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Jack Meehan", "id": 51, "section": [{"id": 52, "text": "Appreciate it.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jack Meehan\", \"section_number\": 28, \"uuid\": \"0e87639d-c490-424b-92f4-61201e15bbb0\", \"speaker_title\": \"Analyst at Nephron Research\"}"}]}, {"title": "Remarks by Puneet Souda", "id": 53, "section": [{"id": 54, "text": "Yeah, hi Karleen. And thanks for taking the question. So I'm just a bit on the sort of the longer-term, I mean you've talked about 5% to 7% you're saying low double-digits here obviously businesses are recovering low capital expense, but more of the recurring revenue that your customers are sending your ways to sort of just talk to us about how should we think about that and is that now a more of a conservative number. And just talk to us about how you think about 5% to 7% longer-term?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Puneet Souda\", \"section_number\": 30, \"uuid\": \"a75446f5-91b0-4c31-b14f-4c9a1fd9ab98\", \"speaker_title\": \"Analyst at SCB Securities\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 55, "section": [{"id": 56, "text": "Yeah, I think long term, we're -- we're sticking with the 5% to 7%, but as we've said all along what sometimes gonna be above, sometimes we'll be a little bit below, I think for where we are right now, we feel very good about delivering certainly above that for next year, but we don't want to get caught up way ahead of ourselves either in saying, we're moving that guidance up by any stretch. It's just that reminder there might be some periods of time where we're a little bit below that and there will be periods were above it. But I think we feel solidly better [Indecipherable] our businesses.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 31, \"uuid\": \"e2163894-dd71-4390-8c1b-44e0e00eac31\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 57, "section": [{"id": 58, "text": "We only gave that range, about 15 months ago. So like we're not, don't need to change it at this point.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 32, \"uuid\": \"aad65fed-e605-4379-8621-9f0b29e1096f\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Puneet Souda", "id": 59, "section": [{"id": 60, "text": "Okay, got it. And then Steve, a broader question for you. Now in the sort of post-pandemic era and again, might have a long tail to it. Do you see heightened utilization for Flu, RSV, other respiratory just continuing on because the awareness but just overall these viruses and overall the significance of just overall diagnostics and routine primary care settings is such that it's going to be sustained just help us understand, do you see a high utilization just the sustaining here for the respiratory businesses for -- for a long time.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Puneet Souda\", \"section_number\": 33, \"uuid\": \"99bb0ad4-8b64-4a20-89d0-20f4672251ee\", \"speaker_title\": \"Analyst at SCB Securities\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 61, "section": [{"id": 62, "text": "Yeah, it's a great quarter to predict because I think we do see probably higher levels of testing going forth. Right, the Diagnostics industry has been elevated and people's desire to know with more certainty what they have even think about something as simple as RSV that we're talking about here in the last few weeks. I'd argue that 99.9% of the public had never heard of RSV even a month ago. Right. So now we're getting into these levels of granularity that people want to know more about and what they have and we think that will be a positive. It's also, both what we're able to offer on our Fusion platform. Also a big piece that Mobi will bring to us in the future and certainly we're seeing that in our European business right now. So I think we're well poised also for the future", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 34, \"uuid\": \"f14119ec-2ebf-417b-9751-d01288cfc22e\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Lisa Garcia", "id": 63, "section": [{"id": 64, "text": "Hi guys, thanks for pulling me in [Phonetic]. Appreciate it. Maybe just to start off on kind of Surgical and tenants expectations there with MyoSure kind of leading the growth for fiscal 2023, can you kind of talk about what kind of gives you confidence. It seems like you have a little bit more optimism about kind of growth expectations for MyoSure in particular, so I'd love to hear kind of what's driving the optimism also kind of -- let's start there.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Lisa Garcia\", \"section_number\": 36, \"uuid\": \"43b1bcf1-9a2a-4a4e-9277-975ebf88e313\", \"speaker_title\": \"Analyst at UBS\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 65, "section": [{"id": 66, "text": "Yeah, I think with MyoSure we just first off bias because we just came back from our U.S. sales meeting last week with that sales team and hard not to be excited when you've been with them, but I think on a more serious and deeper basis MyoSure has been an outsized grower now for seven or eight years long beyond what anybody thought it could be. And I think what we continue to see is, there is still significant opportunities in the fibroids space, there's still to some degree markets that are under-developed and MyoSure procedure is an amazingly positive procedure with great outcomes. And so I think we just continue to, we're not quite sure what the end market truly is there.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 37, \"uuid\": \"94dfcbdc-507e-4346-8a2c-7492a76e5a68\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 67, "section": [{"id": 68, "text": "Yeah, International continues to be a bigger piece of that performance as well -- what gives us confidence in that outlook.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 38, \"uuid\": \"5354f7bb-7835-45d4-8270-f90b78ee1566\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Lisa Garcia", "id": 69, "section": [{"id": 70, "text": "Great. And then can you just update us where you stand with the biotherapeutics [Phonetic], CLIA lab, going into the San Diego headquarters and you're automation initiatives that you have underway and how we should think about timelines for those. And maybe potential impact there.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Lisa Garcia\", \"section_number\": 39, \"uuid\": \"d8065a18-7fdf-418d-973a-b654cd86d7bd\", \"speaker_title\": \"Analyst at UBS\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 71, "section": [{"id": 72, "text": "Yes, sure. The build-out of the lab in our building here in San Diego has gone well that will be happening in the next couple of quarters and we're adding more automation that will really be kicking in, in terms of, particularly the ordering system really early next calendar year. So that team just as continues to crush it since they've been part of the Hologic team, we were just with all of their salespeople last week and they feeling so supported and excited to be a part Hologic and it's part of that classic thing of what we're trying to do is we bring these technologies in and are they are going to be able [Phonetic] to put additional investment in them to accelerate the growth rate, what we've done with Boulder, what we're doing with Acessa, what we're doing with the Biotheranostics team and just feeling great about these opportunities.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 40, \"uuid\": \"c5ff8d47-4a19-4815-b1ee-226be533fa3a\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Max Masucci", "id": 73, "section": [{"id": 74, "text": "Hey, good afternoon. Congrats on a very strong year. First one, if we just think about the Panther installed base, nearly doubling since pre-pandemic times we have an expanding adoption of non-COVID menu items. Is there a logical range level where the non-COVID Panther gross margins have settled or maybe even in broader terms how they go for molecular diagnostics gross margins have evolved since pre-pandemic times?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Max Masucci\", \"section_number\": 42, \"uuid\": \"0ed61381-973d-47c2-84c5-afc83518cb42\", \"speaker_title\": \"Analyst at Cowen and Company\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 75, "section": [{"id": 76, "text": "Yeah, I mean the gross margins on the molecular business -- we've said all along are accretive to the corporate average, but the dynamics of this business is, as we add more of the newer assays, we typically get those at a higher price higher margin but we give some pricing on the legacy assays. So we'll get as we produce more in our San Diego facility, we will obviously naturally gain more absorption. But I think, think about those holding at higher than corporate averages. But I wouldn't see a significant upward trend anytime.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 43, \"uuid\": \"198ac475-2c30-498f-ba2f-0610125025c4\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Max Masucci", "id": 77, "section": [{"id": 78, "text": "Okay, got it. And then the final one $2.3 billion in cash historically low net leverage ratio -- we are seeing, re-calibrating valuations in the public arena. So could you just give us a peek into the Hologic capital allocation playbook, should we assume that buybacks will remain the priority in a choppy market environment with opportunistic M&A sort of sitting in that number two slot in terms of prioritization?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Max Masucci\", \"section_number\": 44, \"uuid\": \"5d130ccb-7bdf-497e-86e1-09ae5aaea04c\", \"speaker_title\": \"Analyst at Cowen and Company\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 79, "section": [{"id": 80, "text": "Max. I would actually reverse that to our capital allocation has consistently been to deploy our free cash flow, which as you noted, has grown over the last couple of years, but the priority is the M&A and share repurchases. It has been more of an ongoing activity at a minimum to manage dilution from our equity plans and as we see opportunities disconnects to jump in and we'll get a little more but priority will be M&A, but we'll be disciplined in that in that strategy.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 45, \"uuid\": \"f2c60892-e49e-4f7b-9a7e-38a8e8d929d5\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 81, "section": [{"id": 82, "text": "Yes, Max, I could build on that. Obviously, if you're looking at last year, we didn't do as much on the M&A front, the previous year, we did a whole bunch. So sometimes the doctors don't look at any given couple of quarters to say that we've changed our strategy. It's really about the opportunities. The other piece I would reiterate is when you have a healthy base business it's also given us the enormous ability to be very patient in doing deals and I think that's the best part of it all is, when your core business is healthy. There is no need to do deals and we can do the ones that makes sense for us. So clearly to reiterate as Karleen said number one is still on the acquisition front.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 46, \"uuid\": \"cbc89fca-6a78-44f4-a2ea-17be4af94201\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Max Masucci", "id": 83, "section": [{"id": 84, "text": "Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Max Masucci\", \"section_number\": 47, \"uuid\": \"0cc86fb4-7732-4c88-ab71-b779ab5389f7\", \"speaker_title\": \"Analyst at Cowen and Company\"}"}]}, {"title": "Remarks by Timothy Daley", "id": 85, "section": [{"id": 86, "text": "Great, thanks for the time here. So my first one is around the kind of broader macro environment. So thinking about the guidance range here, is there any specific non-COVID drivers that you could lay out for us that maybe put you guys at the high end of the guidance range at the low-end or COVID that kind of the big -- big delta there.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Timothy Daley\", \"section_number\": 49, \"uuid\": \"fe436f9a-2dd2-4abb-bc53-cfa8d886de04\", \"speaker_title\": \"Analyst at Wells Fargo\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 87, "section": [{"id": 88, "text": "COVID is not, this is, we're really talking about our base businesses being strong. All three of them.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 50, \"uuid\": \"b89f85fe-cca0-43ef-9bb3-fd1e042e6ae6\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Timothy Daley", "id": 89, "section": [{"id": 90, "text": "Great. And then following up to that are there any concerns that you have around the European geographical footprint particularly relating to some of your third-party OEM partners? Just is that contemplated guidance [Phonetic] any additional details around that would be helpful.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Timothy Daley\", \"section_number\": 51, \"uuid\": \"08ac2cfa-f3a2-4732-a1fe-e09b72146ed9\", \"speaker_title\": \"Analyst at Wells Fargo\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 91, "section": [{"id": 92, "text": "We certainly worry about the geopolitical and particularly the economic scenarios in Europe and I think particularly as this winter comes in energy and everything else I think having said that, that's all the macro. The micro is our teams and our businesses, are just in great shape and I think are poised regardless of the environment to be able to power and deliver through that, thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 52, \"uuid\": \"0e37d89d-b525-4ea8-8221-eca5276876bf\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Unidentified Participant", "id": 93, "section": [{"id": 94, "text": "Good evening. Hope you're doing well.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Unidentified Participant\", \"section_number\": 54, \"uuid\": \"65dbd625-a315-4991-838d-badfa1cb9e4e\", \"speaker_title\": \"at Hologic\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 95, "section": [{"id": 96, "text": "Hey, all right.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 55, \"uuid\": \"b0b18953-fe48-4904-b5d4-fe436d0ebb52\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Unidentified Participant", "id": 97, "section": [{"id": 98, "text": "Hey, how are you? So two questions, first of all, the tax rate going from 21% to 19%. But can you tell us what's driving that. And the second question is going to be what are you assuming in pricing I mean how much of your sort of like double-digit organic revenue growth when you're looking at some of the targets for some of the businesses sort of being driven by price and you know are your diagnostic customers in particular, starting to potentially push back on pricing as COVID reimbursement is likely to go away next year -- the higher -- as the public health emergency goes away. Thanks.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Unidentified Participant\", \"section_number\": 56, \"uuid\": \"01aa3193-529f-4ec4-a0e7-694afa347125\", \"speaker_title\": \"at Hologic\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 99, "section": [{"id": 100, "text": "Yes. So certainly on the tax rate, we continue to look for opportunities to more effectively leverage our supply chain and our operational footprint looking for our low-cost areas, and so a lot of that work has been happening over the last 24 months, which which is driving that lower tax rate down to 19% for 2023 and I think from one aspect of COVID pricing, I think even when the public health does go away, I do think the pricing certainly much more of our discussion with our customers and it's, and it has been yes.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 57, \"uuid\": \"9022df33-dc95-42b2-8cd7-195da73d4474\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 101, "section": [{"id": 102, "text": "Yes, [Indecipherable]. We have very little pricing baked into the numbers we have puts and takes frankly across franchises across geographies. And just to give a plug for Karleen [Indecipherable] everybody has always admired, our operating margin piece, but we've been very focused on the net side and our tax team has been working very hard over the last few years and they are doing a great, great job to really kind of show up this year with another opportunity for us to continue to drive that net margin.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 58, \"uuid\": \"3d14c955-8d6d-498a-b22d-373c2f8f1840\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Unidentified Participant", "id": 103, "section": [{"id": 104, "text": "And would you use 19% [Phonetic] of the go-forward rate?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Unidentified Participant\", \"section_number\": 59, \"uuid\": \"8b50d3c1-beb6-4413-a697-e75669a3720f\", \"speaker_title\": \"at Hologic\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 105, "section": [{"id": 106, "text": "Yes. At this point, I would unless there is a change in the federal statutory rate, I think 19% is good to.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 60, \"uuid\": \"04210f29-7a79-48b9-a715-7e0c34242891\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}, {"title": "Remarks by Stephen MacMillan", "id": 107, "section": [{"id": 108, "text": "Thank you, [Indecipherable].", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Stephen MacMillan\", \"section_number\": 61, \"uuid\": \"69ff6c77-ecf1-4559-9dfe-b064179c313f\", \"speaker_title\": \"Chairman, President and Chief Executive Officer at Hologic\"}"}]}, {"title": "Remarks by Casey Woodring", "id": 109, "section": [{"id": 110, "text": "Hi guys, thanks for fitting me. I guess just so last time we spoke, I think you guys are pointing to a pre-COVID operating margin of 31.5% from 2Q '20. It was just a good place to start for '23 as COVID would maybe balance out some of the supply chain headwinds, so curious just on the 30% number here. Can you maybe quantify what the basis point headwind from the supply chain dynamics on the year and then maybe could you also quantify how much lower, the international business operating margin is in relation to the total company number? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Casey Woodring\", \"section_number\": 63, \"uuid\": \"e219cf9f-1573-4171-9f12-9cb42dd0fb47\", \"speaker_title\": \"Analyst at JP Morgan\"}"}]}, {"title": "Remarks by Karleen Oberton", "id": 111, "section": [{"id": 112, "text": "Yes. I think from the supply chain from the higher cost is roughly 200 to 250 basis points on the operating margin that yes [Phonetic] we have forecasted would persist through 2023. We have, we have talked about international margins being lower than the US, but we have not disclosed the difference, but I think certainly there is discussions. Our teams are focused on improving their leverage as we move forward.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Karleen Oberton\", \"section_number\": 64, \"uuid\": \"0ceeac67-83c2-4c10-8ca4-c78e708923c9\", \"speaker_title\": \"Chief Financial Officer at Hologic\"}"}]}], "title": "Q&A for HOLX (Hologic) on 10/31/22 4:30 PM ET", "metadata_json": "{\"company_name\": \"Hologic\", \"company_ticker\": \"HOLX\", \"transcript_date\": \"10/31/22 4:30 PM ET\", \"section_type\": \"Q&A\", \"transcript_url\": \"https://www.marketbeat.com/earnings/transcripts/80634/\"}"}